ASCO posters and presentations

Showcasing our efforts at one of oncology's biggest international meetings

In collaboration with various oncology groups, the CTC are proud to present the following talks and posters at the American Society of Clinical Oncology (ASCO) 13th Annual Meeting currently being held in Chicago.

  1. Brulé S, Jonker D, Karapetis C, O'Callaghan C, Moore M, Wong R, Tebbutt N, Underhill C, Yip D, Zalcberg J, Tu D, Goodwin R. Location of colon cancer (right-sided versus left-sided) as a predictor of benefit from cetuximab in NCIC CTG CO.17. abstract 3528.
  2. Casali P, LeCesne A, Valasco A, Kotasek D, Rutkowski P, Hohenberger P, Fumagalli E, Judson I, Italiano A, Broto J, Gronchi A, Dei Tos A, Marreaud S, Van Der Graaf W, Zalcberg J, Litière S, Blay J, EORTC Soft Tissue and Bone Sarcoma Group (EORTC STBSG), French Sarcoma Group (FSG), Italian Sarcoma Group (ISG), Grupo Español de Investigación en Sarcomas (GEIS), Australasian Gastro-Intestinal Trials Group (AGITG). Imatinib failure-free survival in patients with localized gastrointestinal stromal tumors treated with adjuvant imatinib: the EORTC/AGITG/FSG/GEIS/ISG randomized controlled phase III trial. abstract 10500.
  3. Cosman R, Brown C, DeBraganca K, Khasraw M, Cooperative Trials Group for Neuro-Oncology. Patterns of care study of adult medulloblastoma. abstract 2086.
  4. Field K, Simes J, Wheeler H, Hovey E, Nowak A, Cher L, Brown C, Livingstone A, Sawkins K, Rosenthal M, CABARET/COGNO Investigators. A randomised phase II study of carboplatin and bevacizumab in recurrent glioblastoma multiforme (CABARET). Abstract 2017.
  5. Fox P, Gao B, Balakrishnar B, Menzies A, Yeap S, Ali S, Gebski V, Provan P, Coulter S, Liddle C, Hui R, Kefford R, Lynch J, Wilcken N, Balleine R, Gurney H. Factors predicting endoxifen levels in breast cancer patients taking standard-dose tamoxifen and following dose escalation. Abstract 543.
  6. Friedlander M, Sjoquist K, Sommeijer D, Bailey L, Martyn J, Gillies K, Mileshkin L, O'Connell R, Gebski V, Vaughan M, Blomfield P, Beale P, Quinn M, Stockler M, Lombard J, Hadley A, Amant F, Edmondson R. PARAGON: Phase II study of aromatase inhibitors in women with potentially hormone responsive recurrent/metastatic gynecologic neoplasms: ANZGOG 0903. abstract TPS5614.
  7. Hammel P, Huguet F, Van Laethem JL, Goldstein D, Glimelius B, Artru P, Borbath I, Bouche O, Shannon J, André T, Mineur L, Chibaudel B, Bonnetain F, Louvet C. Comparison of chemoradiotherapy and chemotherapy in patients with a locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: final results of the international phase III LAP 07 study. American Society of Clinical Oncology Annual Meeting; 31 May-4 Jun 2013; Chicago.
  8. Horvath L, Chatfield M, Lee-Ng M, Lin H-M, Castillo L, Breit S, Brown D, Molloy M, Marx G, Pavlakis M, Boyer M, Stockler M, Wykes R, Henshall S, Mahon K. The role of macrophages in docetaxel resistance in castrate-resistant prostate cancer. abstract e22175.
  9. Pavlakis M, Goldstein D, Sjoquist K, Martin A, Tsobanis E, Yip S, Shannon J, Burge M, Cronk M, Tebbutt N, Strickland A, Lipton L, Price T, Nott L, Harris D, Burnell M, Alcindor T, Bang Y, Kang Y, O'Callaghan C. INTEGRATE: A randomized phase II double-blind placebo-controlled study of regorafenib in refractory advanced esophagogastric cancer-a study by the Australasian Gastrointestinal Trials Group (AGITG). Abstract TPS4157.
  10. Rischin D, Matei D, Goh J, Vaughan M, Beale P, Tenney M, Martyn J, Sommeijer D, Iglesias J, Bibby D, Simpson J, Doolin E, Williams C, Stockler M. A phase I/II study of the vascular disrupting agent BNC105P in combination with gemcitabine-carboplatin in partially platinum-sensitive ovarian cancer patients in first or second relapse: An international collaborative group trial of ANZGOG and HOG. abstract TPS5612.
  11. Schmoll H, Haustermans K, Price T, Nordlinger B, Hofheinz R, Daisne J, Janssens J, Brenner B, Schmidt P, Reinel H, Hollerbach S, Caca K, Fauth F, Hannig C, Zalcberg J, Tebbutt N, Mauer M, Messina C, Lutz M, Van Cutsem E, for the EORTC GITCG A, AGITG, EORTC ROG, BGDO, FFCD,. Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin versus capecitabine alone in locally advanced rectal cancer: First results of the PETACC-6 randomized phase III trial. abstract 3531.
  12. Segelov E, Wilson K, Gebski V, Waring P, Tabernero J, Wasan H, Ciardiello F, Desai J, Underhill C, Karapetis C, Khasraw M, Nott L, Joubert W, Pavlakis M, Van Hazel G, Chantrill L, Price T, Jefford M, Haydon A, Shapiro J. ICE CREAM: Irinotecan cetuximab evaluation and the cetuximab response evaluation among patients with G13D mutation. Abstract TPS3649.
  13. Sommeijer D, Shi Q, Meyers J, Sjoquist K, Hoff P, Seymour M, Cassidy J, Goldberg R, Douillard J, Hecht J, Hurwitz H, Tournigand C, Tebbutt N, Aranda E, Souglakos J, Kabbinavar F, Chibaudel B, De Gramont A, Sargent D, Zalcberg J, for the ARCAD Group. Prognostic value of early objective tumor response to first-line systemic therapy in metastatic colorectal cancer: individual patient data meta-analysis of randomized trials from the ARCAD database. abstract 3520.
  14. Stockler M, Hilpert F, Friedlander M, King M, Wenzel L, Lee C, Joly F, De Gregorio N, Arija J, Raza Mirza M, Sorio R, Freudensprung U, Sneller V, Hales G, Pujade-Lauraine E, AURELIA Investigators. Health-related quality of life results from the AURELIA trial evaluating bevacizumab plus chemotherapy for platinum-resistant recurrent ovarian cancer. abstract 5542.
  15. Tebbutt N, Price T, Sjoquist K, Veillard A, Hall M, Ferraro D, Wong N, Pavlakis M, Strickland A, Varma S, Cooray P, Young R, Underhill C, Shannon J, Ganju V, Gebski V, Group. AGT. Final results of AGITG ATTAX3 study: randomized phase II study of weekly docetaxel, cisplatin, and fluoropyrimidine with or without panitumumab in advanced esophagogastric cancer. Abstract 4081.
  16. Tjokrowidjaja A, Lee C, Stockler M. Does chemotherapy improve survival in muscle-invasive bladder cancer? A systematic review and meta-analysis of randomized controlled trials. Abstract 4544.
  17. Vickers M, Tu D, Lee C, Wheatley-Price P, Parulekar W, GBrundage M, Moore M, Au H, O'Callaghan C, Jonker D, Ringash J, Goldstein D. Significance of baseline quality of life scores in predicting clinical outcomes in an international phase III trial of advanced pancreatic cancer: NCIC CTG PA.3. Abstract 4053.
  18. Weickhardt A, Nguyen T, Paskulin D, Le A, Aisner D, Schulte N, Chionh F, Mariadason J, Tebbutt N. ALK and ROS1 gene rearrangements detected in colorectal cancer by fluorescence in situ hybridization. Abstract 3545.